TipRanks
Advertisement
Advertisement
Janux Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
PremiumThe FlyJanux Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
2M ago
Analyst Maintains Buy on Janux Therapeutics, Keeps $60 Price Target Unchanged on Strong Balance Sheet and Clinical Differentiation
Premium
Ratings
Analyst Maintains Buy on Janux Therapeutics, Keeps $60 Price Target Unchanged on Strong Balance Sheet and Clinical Differentiation
2M ago
Janux Therapeutics price target lowered to $35 from $38 at Stifel
Premium
The Fly
Janux Therapeutics price target lowered to $35 from $38 at Stifel
2M ago
Closing Bell Movers: FedEx slumps 6% after results
PremiumThe FlyClosing Bell Movers: FedEx slumps 6% after results
4M ago
Janux Therapeutics Announces Departure of Chief Medical Officer
Premium
Company Announcements
Janux Therapeutics Announces Departure of Chief Medical Officer
4M ago
Janux Therapeutics reports departure of Chief Medical Officer
Premium
The Fly
Janux Therapeutics reports departure of Chief Medical Officer
4M ago
Janux Therapeutics price target lowered to $26 from $30 at Piper Sandler
PremiumThe FlyJanux Therapeutics price target lowered to $26 from $30 at Piper Sandler
5M ago
Analyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value
Premium
Ratings
Analyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value
5M ago
Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14
Premium
Ratings
Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14
5M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―